CNS Pharmaceuticals (CNSP) has provided an announcement.
CNS Pharmaceuticals, Inc. faces a challenge maintaining its Nasdaq listing after the stock price fell below the $1 minimum bid requirement for 30 days. While there’s no immediate threat to its listing, the company must boost its share price to meet Nasdaq’s standards by August 26, 2024, or potentially undergo measures like a reverse stock split. This comes alongside the appointment of new members to its Board committees, signaling internal shifts as the company navigates financial compliance issues.
For a thorough assessment of CNSP stock, go to TipRanks’ Stock Analysis page.
